Tesaro shares climb as nausea drug hits phase III endpoints
By Michael Fitzhugh
Tuesday, May 13, 2014
Investors drove Tesaro Inc. shares up 21 percent Monday (NASDAQ:TSRO) on news that the company hit both its primary and secondary endpoints in a phase III trial of rolapitant, its top hope for breaking into the $1.5 billion U.S. market for drugs preventing chemotherapy-induced nausea and vomiting (CINV).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.